Postprandial glucose-management strategies in type 1 diabetes: Current approaches and prospects with precision medicine and artificial intelligence

被引:0
|
作者
Jafar, Adnan [1 ]
Pasqua, Melissa-Rosina [2 ]
机构
[1] McGill Univ, Dept Biomed Engn, 3775 Univ St, Montreal, PQ H3A 2B4, Canada
[2] McGill Univ, Dept Med, Div Endocrinol, Montreal, PQ, Canada
关键词
deep reinforcement learning; foundation models; macronutrients; physical activity; precision medicine; type; 1; diabetes; MULTIPLE DAILY INJECTIONS; RAPID-ACTING INSULIN; PHYSICAL-ACTIVITY; BOLUS CALCULATOR; GLYCEMIC CONTROL; MODERATE EXERCISE; PLASMA-GLUCOSE; HIGH-INTENSITY; PROTEIN MEAL; HYPOGLYCEMIA;
D O I
10.1111/dom.15463
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Postprandial glucose control can be challenging for individuals with type 1 diabetes, and this can be attributed to many factors, including suboptimal therapy parameters (carbohydrate ratios, correction factors, basal doses) because of physiological changes, meal macronutrients and engagement in postprandial physical activity. This narrative review aims to examine the current postprandial glucose-management strategies tested in clinical trials, including adjusting therapy settings, bolusing for meal macronutrients, adjusting pre-exercise and postexercise meal boluses for postprandial physical activity, and other therapeutic options, for individuals on open-loop and closed-loop therapies. Then we discuss their challenges and future avenues. Despite advancements in insulin delivery devices such as closed-loop systems and decision-support systems, many individuals with type 1 diabetes still struggle to manage their glucose levels. The main challenge is the lack of personalized recommendations, causing suboptimal postprandial glucose control. We suggest that postprandial glucose control can be improved by (i) providing personalized recommendations for meal macronutrients and postprandial activity; (ii) including behavioural recommendations; (iii) using other personalized therapeutic approaches (e.g. glucagon-like peptide-1 receptor agonists, sodium-glucose co-transporter inhibitors, amylin analogues, inhaled insulin) in addition to insulin therapy; and (iv) integrating an interpretability report to explain to individuals about changes in treatment therapy and behavioural recommendations. In addition, we suggest a future avenue to implement precision recommendations for individuals with type 1 diabetes utilizing the potential of deep reinforcement learning and foundation models (such as GPT and BERT), employing different modalities of data including diabetes-related and external background factors (i.e. behavioural, environmental, biological and abnormal events).
引用
收藏
页码:1555 / 1566
页数:12
相关论文
共 15 条
  • [1] Blood glucose level prediction in type 1 diabetes: A comparative analysis of interpretable artificial intelligence approaches
    Basile, Ilaria
    Sannino, Giovanna
    RESULTS IN ENGINEERING, 2025, 25
  • [2] Technology in the management of type 1 diabetes mellitus - current status and future prospects
    Tauschmann, Martin
    Hovorka, Roman
    NATURE REVIEWS ENDOCRINOLOGY, 2018, 14 (08) : 464 - 475
  • [3] Exercise and type 1 diabetes: treatment strategies and glucose management
    Moser, Othmar
    Thurm, Ulrike
    DIABETOLOGIE, 2024, 20 (06): : 724 - 730
  • [4] The Artificial Pancreas and Meal Control AN OVERVIEW OF POSTPRANDIAL GLUCOSE REGULATION IN TYPE 1 DIABETES
    El Fathi, Anas
    Smaoui, Mohamed Raef
    Gingras, Veronique
    Boulet, Benoit
    Haidar, Ahmad
    IEEE CONTROL SYSTEMS MAGAZINE, 2018, 38 (01): : 67 - 85
  • [5] An artificial intelligence decision support system for the management of type 1 diabetes
    Tyler, Nichole S.
    Mosquera-Lopez, Clara M.
    Wilson, Leah M.
    Dodier, Robert H.
    Branigan, Deborah L.
    Gabo, Virginia B.
    Guillot, Florian H.
    Hilts, Wade W.
    El Youssef, Joseph
    Castle, Jessica R.
    Jacobs, Peter G.
    NATURE METABOLISM, 2020, 2 (07) : 612 - +
  • [6] Families' reports of problematic foods, management strategies and continuous glucose monitoring in type 1 diabetes: A cross-sectional study
    Smith, Tenele A.
    Blowes, Ashley A.
    King, Bruce R.
    Howley, Peter P.
    Smart, Carmel E.
    NUTRITION & DIETETICS, 2021, 78 (04) : 449 - 457
  • [7] A review on artificial pancreas and regenerative medicine used in the management of Type 1 diabetes mellitus
    Sachdeva P.
    Ashrit R.M.
    Shukla R.
    Sahani A.
    Journal of Medical Engineering and Technology, 2022, 46 (08) : 693 - 702
  • [8] Towards Precision Behavioral Medicine with IoT: Iterative Design and Optimization of a Self-Management Tool for Type 1 Diabetes
    Zhang, Peng
    Schmidt, Douglas C.
    White, Jules
    Mulvaney, Shelagh A.
    2018 IEEE INTERNATIONAL CONFERENCE ON HEALTHCARE INFORMATICS (ICHI), 2018, : 64 - 74
  • [9] Use of a do-it-yourself artificial pancreas system is associated with better glucose management and higher quality of life among adults with type 1 diabetes
    Wu, Zekai
    Luo, Sihui
    Zheng, Xueying
    Bi, Yan
    Xu, Wen
    Yan, Jinhua
    Yang, Daizhi
    Weng, Jianping
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2020, 11
  • [10] Equitable implementation of a precision digital health program for glucose management in individuals with newly diagnosed type 1 diabetes
    Prahalad, Priya
    Scheinker, David
    Desai, Manisha
    Ding, Victoria Y.
    Bishop, Franziska K.
    Lee, Ming Yeh
    Ferstad, Johannes
    Zaharieva, Dessi P.
    Addala, Ananta
    Johari, Ramesh
    Hood, Korey
    Maahs, David M.
    NATURE MEDICINE, 2024, 30 (07) : 2067 - 2075